Skip to main content
Premium Trial:

Request an Annual Quote

RXi Aims for First Clinical Trial in 2012

Premium

RXi Pharmaceuticals this week said that it has begun formal development of its lead dermal anti-scarring candidate RXI-109, and expects to submit an investigational new drug application for the compound in the second half of the year, with human testing beginning in 2012.

The company also said that it plans to test the safety and efficacy of the drug in the first clinical trial of RXI-109. Specifically, RXi said that it will evaluate the agent's ability to reduce dermal scarring in planned surgeries.

“By evaluating RXI-109's effect on scar formation in this proposed trial, not only will we be able to gather safety and tolerability data, we believe we may also be able to obtain an early histological assessment of clinical efficacy within the first year of initiating this trial,” Pamela Pavco, vice president of pharmaceutical development at RXi, said in a statement.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.